ECOG‑ACRIN Cancer Research Group

ECOG‑ACRIN Cancer Research Group
Name	ECOG‑ACRIN Cancer Research Group
Formation	1955 (ECOG), 1998 (ACRIN), 2012 (merger)
Headquarters	United States
Type	Clinical trials cooperative group
Purpose	Oncology clinical research
Region served	United States, international

Contents

ECOG‑ACRIN Cancer Research Group is a cooperative oncology research organization formed by the merger of two legacy groups to design and conduct multicenter clinical trials in adult oncology. The group operates within a network of academic medical centers such as Dana‑Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, and Johns Hopkins Hospital, collaborating with federal agencies including the National Cancer Institute and the National Institutes of Health. It plays a central role in trials that influence practice at institutions like Memorial Sloan Kettering Cancer Center, UCSF Medical Center, Cleveland Clinic, and Massachusetts General Hospital.

History

The group traces roots to the ECOG founded in 1955 and the ACRIN established in 1998, culminating in a 2012 merger motivated by strategic alignment with the National Cancer Act era priorities and the National Clinical Trials Network. Early milestones involved partnerships with centers such as Fred Hutchinson Cancer Research Center, Roswell Park Comprehensive Cancer Center, Vanderbilt University Medical Center, and University of Pennsylvania Health System. The merged organization has navigated policy shifts from administrations under presidents like Dwight D. Eisenhower, Richard Nixon, and Barack Obama in parallel with scientific advances exemplified by breakthroughs at Stanford University and Columbia University Irving Medical Center.

Governance includes an executive committee, scientific steering committees, and institutional members drawn from universities like University of Michigan, Yale School of Medicine, Northwestern Memorial Hospital, and University of Chicago Medicine. Leadership interacts with boards and advisory panels that have affinities with entities such as American Association for Cancer Research, American Society of Clinical Oncology, Association of American Medical Colleges, and ClinicalTrials.gov stakeholders. Regulatory coordination extends to Food and Drug Administration consultations and cooperative agreements with the Centers for Medicare & Medicaid Services. Institutional Review Boards at sites including University of California, Los Angeles, University of Washington, and Emory University School of Medicine review protocols.

Programs span adult solid tumor and hematologic malignancy trials with oncology portfolios that intersect research at Harvard Medical School, Cornell University, Rutgers University, University of Texas Southwestern Medical Center, and Ohio State University. Major trial areas encompass breast cancer collaborations with Dana‑Farber Cancer Institute and Brigham and Women's Hospital, lung cancer studies connected to Memorial Sloan Kettering Cancer Center and Stanford Cancer Institute, and hematology protocols alongside Fred Hutchinson Cancer Research Center and Mayo Clinic Cancer Center. Imaging and biomarker substudies involve partnerships with National Institutes of Health Clinical Center divisions, technology transfer offices linked to MIT, and diagnostic groups at Johns Hopkins School of Medicine. The group has conducted randomized controlled trials using methodologies refined by statisticians from Columbia University, University of California, San Diego, and Duke University School of Medicine.

Contributions include practice‑changing trial results influencing therapy standards at Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, UCLA Health, and Mount Sinai Health System. Findings on adjuvant chemotherapy informed protocols used at Mayo Clinic, while imaging validation studies impacted guidelines published by panels affiliated with American Society of Clinical Oncology and National Comprehensive Cancer Network. The group’s biomarker research advanced companion diagnostics adopted in centers like Massachusetts General Hospital Cancer Center, and outcomes research informed reimbursement discussions with Centers for Medicare & Medicaid Services. Publications in high‑impact venues mirror work from investigators at Weill Cornell Medicine, Wake Forest School of Medicine, and Brown University.

Funding streams include competitive grants from the National Cancer Institute, cooperative agreements with the National Institutes of Health, investigator‑initiated support from foundations such as the American Cancer Society and philanthropic gifts to institutions like Dana‑Farber Cancer Institute. Industry collaborations involve pharmaceutical partners with portfolios at companies comparable to those working with Pfizer, Roche, Merck, and Bristol Myers Squibb on oncology therapeutics. International collaborations touch centers such as University College London Hospitals, Princess Margaret Cancer Centre, and Peter MacCallum Cancer Centre, and cooperative activities align with global consortia including International Agency for Research on Cancer initiatives.

Training programs engage trainees from medical schools and residency programs at Johns Hopkins University School of Medicine, University of California, San Francisco, University of Pennsylvania Perelman School of Medicine, and Columbia University Vagelos College of Physicians and Surgeons through mentorship, protocol development workshops, and biostatistics courses offered in partnership with departments at Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, and Yale School of Public Health. Community outreach initiatives coordinate with cancer centers including Flagship hospitals and public health departments like those in New York City, Chicago, and Boston to improve trial access among diverse populations represented in registries at SEER Program‑affiliated institutions. Educational outputs include investigator meetings, continuing medical education in collaboration with American Society of Clinical Oncology, and trainee scholarships supported by academic societies such as Society of Gynecologic Oncology and American Society of Hematology.

Category:Oncology research organizations